Posted on: January 17, 2020
Lorne Hofseth, Ph.D., professor in Drug Discovery and Biomedical Sciences and director of the Center for Colon Cancer Research, has received a $1.7 million R01 grant from the National Institutes of Health to study the effects of a ginseng molecule that may positively impact the future treatment of colon cancer. The grant will be awarded over five years.
The study, titled “Harnessing the Power of P53 with Panaxynol from American Ginseng to Suppress Colitis and Prevent Colon Cancer,” will allow Hofseth’s team team to further research how the mechanism by which American Ginseng may eliminate colon cancer. Hofseth’s team seeks to discover the potential advantages and efficacies Ginseng may offer compared to FDA-approved drugs or other complementary / alternative medicines.
Colon cancer is one of the most preventable of all cancers, yet it is also one of the most commonly diagnosed among both men and women according to the American Cancer Society.
The results of this study could essentially add another layer of protection against ever developing colon cancer.
Lorne Hofseth, Ph.D. Director, Center for Colon Cancer Research
“The results of this study could essentially add another layer of protection against ever developing colon cancer,” Hofseth said.
According to College of Pharmacy Dean Stephen J. Cutler, receiving an R01 grant from the NIH is a testament to the quality of work performed by the scientist. “This award is the gold standard we use to measure a scientist’s ability to conduct independent research,” he said. “Dr. Hofseth is an exceedingly accomplished scientist and we are fortunate that he serves as a faculty member in the College of Pharmacy.”